The companies will continue to evaluate the 26 compounds and expect to synthesize multiple candidates for further testing. Dr. Amit Kumar, president and CEO of Anixa, noted the compounds are so novel that the companies have begun drafting a U.S. patent.

Axia and OntoChem previously used in silico screening to identify four compounds that could disrupt the function of endoribonuclease (also known as nonstructural protein-15; NSP-15). They will continue performing biological testing on the initial four molecules going forward, according to Dr. Lutz Weber, CEO of OntoChem.

Anixa, OntoChem screen SARS-CoV-2 main protease inhibitors
Anixa Biosciences and OntoChem have completed in silico screening of four compounds that could function as SARS-CoV-2 main protease inhibitors.

Does SARS-CoV-2 use host defenses to infect susceptible cells?
A new study pinpoints the most likely cell types that SARS-CoV-2 infects. Unexpectedly, the study indicates that one of the body's main defenses against...

Scientists explore SARS-CoV-2 main protease as a drug target
A team of researchers report the structure of the main protease of the novel coronavirus and have identified several drugs that show promise in combating...